Zamvil SS - Search Results

1

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS. Weber MS, et al. Among authors: zamvil ss. Nat Med. 2007 Aug;13(8):935-43. doi: 10.1038/nm1620. Epub 2007 Aug 5. Nat Med. 2007. PMID: 17676050

2

Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis.

Stüve O, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Curr Opin Neurol. 1999 Aug;12(4):395-401. doi: 10.1097/00019052-199908000-00005. Curr Opin Neurol. 1999. PMID: 10555827 Review.

3

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.

Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Soos JM, et al. Among authors: zamvil ss. J Immunol. 2002 Sep 1;169(5):2231-5. doi: 10.4049/jimmunol.169.5.2231. J Immunol. 2002. PMID: 12193686

4

Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS.

Zamvil SS, Steinman L. Zamvil SS, et al. Neurology. 2002 Oct 8;59(7):970-1. doi: 10.1212/wnl.59.7.970. Neurology. 2002. PMID: 12370448 No abstract available.

5

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Youssef S, et al. Among authors: zamvil ss. Nature. 2002 Nov 7;420(6911):78-84. doi: 10.1038/nature01158. Nature. 2002. PMID: 12422218

6

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. J Immunol. 2002 Dec 15;169(12):6720-32. doi: 10.4049/jimmunol.169.12.6720. J Immunol. 2002. PMID: 12471103

7

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.

Zamvil SS, Steinman L. Zamvil SS, et al. Neuron. 2003 Jun 5;38(5):685-8. doi: 10.1016/s0896-6273(03)00326-x. Neuron. 2003. PMID: 12797954 Free article. Review.

8

Approved and future pharmacotherapy for multiple sclerosis.

Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Neurologist. 2002 Sep;8(5):290-301. doi: 10.1097/00127893-200209000-00002. Neurologist. 2002. PMID: 12803676

9

Statins as potential therapeutic agents in neuroinflammatory disorders.

Stüve O, Youssef S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Curr Opin Neurol. 2003 Jun;16(3):393-401. doi: 10.1097/01.wco.0000073942.19076.d1. Curr Opin Neurol. 2003. PMID: 12858078 Review.

10

Statins and their potential targets in multiple sclerosis therapy.

Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Expert Opin Ther Targets. 2003 Oct;7(5):613-22. doi: 10.1517/14728222.7.5.613. Expert Opin Ther Targets. 2003. PMID: 14498824 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page